文献速递肝病消化道肿瘤与早癌

肝细胞癌(HCC)诊断时无转移患者的生存获益与年龄无关:一项基于人群的研究

Age independent survival benefit for patients with hepatocellular carcinoma (HCC) without metastases at diagnosis: a population-based study.
PubMed 文献 · Gut · 2019-03-16

该研究基于慕尼黑癌症登记处1998至2016年诊断的4078例肝细胞癌(HCC)患者,分析肿瘤特征与生存结局。结果显示HCC发病率基本稳定,诊断分期趋早,中位年龄增加;3年相对生存率从1998-2002年的19.8%升至2013-2016年的31.0%,中位总生存从6个月延长至12个月,但生存改善仅见于诊断时无转移的患者,转移患者预后未变。

要点

  • HCC发病率在德国代表地区基本稳定,诊断分期趋早但中位诊断年龄增加。
  • 3年相对生存率从1998-2002年的19.8%升至2013-2016年的31.0%。
  • 生存改善仅见于诊断时无转移患者,转移患者预后未变。

核心结论

  • 真实世界数据显示,与当前假设相反,HCC发病率在德国代表地区并未增加。
  • 更早的诊断(可能与筛查项目实施有关)转化为有效治疗选择的增加以及诊断时无转移患者的明确生存获益,且与年龄无关。

研究设计与样本

  • 基于慕尼黑癌症登记处1998至2016年诊断的4078例HCC患者的人群研究。
  • 按时间段、年龄及诊断时有无转移分析肿瘤特征和结局。
  • 采用Kaplan-Meier法分析总生存(OS),计算相对生存(RS)用于癌症特异性生存,并使用Cox比例风险模型控制预后变量。

主要发现

  • HCC发病率基本稳定,肿瘤诊断分期趋早,但中位诊断年龄增加。
  • 3年RS从1998-2002年的19.8%、2003-2007年的22.4%、2008-2012年的30.6%升至2013-2016年的31.0%。
  • 中位OS从1998-2002年的6个月延长至2008-2016年的12个月。
  • 按转移状态分析显示,生存改善仅见于诊断时无转移的患者,而转移患者预后未变。

临床怎么用

  • 作者认为,更早的诊断(可能与筛查项目实施有关)转化为有效治疗选择的增加以及诊断时无转移患者的明确生存获益,且与年龄无关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Hepatocellular carcinoma (HCC) is a major cause of death worldwide and its incidence is expected to increase globally. Aim of this study was to assess whether the implementation of screening policies and the improvement of treatment options translated into a real-world survival benefit in HCC patients. DESIGN: 4078 patients diagnosed with HCC between 1998 and 2016 from the Munich Cancer Registry were analysed. Tumour characteristics and outcome were analysed by time period and according to age and presence of metastases at diagnosis. Overall survival (OS) was analysed using Kaplan-Meier method and relative survival (RS) was computed for cancer-specific survival. Cox proportional hazard models were conducted to control for prognostic variables. RESULTS: While incidence of HCC remained substantially stable, tumours were diagnosed at increasingly earlier stages, although the median age at diagnosis increased. The 3 years RS in HCC improved from 19.8% in 1998-2002, 22.4% in 2003-2007, 30.6% in 2008-2012 up to 31.0% in 2013-2016. Median OS increased from 6 months in 1998-2002 to 12 months in 2008-2016. However, analysis according to the metastatic status showed that survival improved only in patients without metastases at diagnosis whereas the prognosis of patients with metastatic disease remained unchanged. CONCLUSION: These real-world data show that, in contrast to the current assumptions, the incidence of HCC did not increase in a representative German region. Earlier diagnosis, likely related to the implementation of screening programmes, translated into an increasing employment of effective therapeutic options and a clear survival benefit in patients without metastases at diagnosis, irrespective of age.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. De Toni EN, Schlesinger-Raab A, Fuchs M, et al. Age independent survival benefit for patients with hepatocellular carcinoma (HCC) without metastases at diagnosis: a population-based study. Gut. 2019. PMID: 30878947. doi:10.1136/gutjnl-2018-318193

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。